Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $709

Benzinga Newsdesk www.benzinga.com Positive 89.1%

Neg 0% Neu 0% Pos 89.1%

Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $640 to $709.